Management is re-underwriting a specific asset or business at a value far above its cost, using fresh third-party marks
The model's full reasoning — Q4 2022 call → NOThe question asks whether management puts a concrete, externally-derived value on something the company already owns or controls, and conveys that this value is far above what the company paid, carries it at, or what the company's current results would imply. Let me review the transcript for any such discussion. The call covers: - MRD business (clonoSEQ) - revenue, volumes, growth - Immune Medicine business - pharma services, drug discovery - Genentech partnership - cell therapy programs - Financial results and guidance Key items discussed: - clonoSEQ test volumes, ASP (~$1,100 per test, expected to grow to $1,700) - MRD pharma partnerships, milestones - Genentech collaboration - two cell therapy programs, IND filing expected - Internal autoimmune programs - Revenue guidance, OpEx guidance Is there any discussion of a specific asset being valued against an outside reference point? The Genentech partnership is discussed in terms of milestones and progress, but I don't see management pricing a specific holding against an outside market reference. They discuss the potential IND acceptance milestone ($7 million of $10 million upfront recognized on acceptance), but this is a contractual milestone, not a valuation of an asset against an outside reference. The clonoSEQ ASP discussion mentions a target of $1,700 per test as a contracted rate with private payers, but this is about pricing, not valuing an asset. There's no discussion of: - A stake in another company being valued at market - A division or asset being valued against comparable transactions - An appraisal or third-party offer - Replacement cost versus book value The discussion is entirely about operating results, growth, guidance, and pipeline progress. No specific asset is being re-underwritten at market value using external evidence. Therefore, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TTI | TETRA Technologies, Inc. | Q1 2024 | 2024-05-01 | A |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
TTI · Q1 2024 → YESThe question is: Does management put a CONCRETE, EXTERNALLY-DERIVED VALUE ON SOMETHING THE COMPANY ALREADY OWNS OR CONTROLS, and convey that this value is far above what the company paid, carries it a...YES Management identifies a specific asset: its holdings in Standard Lithium and Kodiak Gas Services (marketable securities worth slightly over $13 million, with total marketable securities around $30 million). It grounds the value in an external reference—the recent Kodiak acquisition of CSI Compressco, which made the stake “very favorable to TETRA,” plus Kodiak’s $2.5 billion market cap and strong trading volumes that allow quick, low-pressure monetization.
GPRE · Q4 2023 → YESThe question is: Does management put a CONCRETE, EXTERNALLY-DERIVED VALUE ON SOMETHING THE COMPANY ALREADY OWNS OR CONTROLS, and convey that this value is far above what the company paid, carries it a...YES Todd Becker explicitly identifies the company's ethanol plants as the specific asset being valued. He states that a high-quality plant trades in the private market at $1.80–$2.00 per gallon (or $2–$2.50 to build from scratch), while the company's overall market cap and net debt imply a lower value for its ~950 million gallon capacity.
AFL · Q2 2023 → YESThe question is: Does management put a CONCRETE, EXTERNALLY-DERIVED VALUE ON SOMETHING THE COMPANY ALREADY OWNS OR CONTROLS, and convey that this value is far above what the company paid, carries it a...YES Management identifies the specific equity stake in Varagon Capital (a minority interest they already held) and grounds its value in the external transaction where Man Group is acquiring Varagon.